KIN Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into KIN

Also see:
KIN stock yearly return 2011
KIN stock yearly return 2012
KIN stock yearly return 2013
KIN stock yearly return 2014
KIN stock yearly return 2015
KIN stock yearly return 2016
KIN stock yearly return 2017
KIN stock yearly return 2018
KIN stock yearly return 2019
KIN stock yearly return 2020
KIN YTD return
Compare KIN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 12/12/2013
End date: 08/27/2021
Start price/share: $11.95
End price/share: $9.25
Dividends collected/share: $0.00
Total return: -22.59%
Average Annual Total Return: -3.27%
Starting investment: $10,000.00
Ending investment: $7,738.96
Years: 7.71

KIN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta™, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; and KIND-025, a canine fusion protein targeting IL-4 and IL-13, for the treatment of atopic dermatitis in dogs. The KIN average annual return 10 years is shown above.

The Average Annual Return on the KIN average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether KIN average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the KIN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for KIN:
KIN SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kindred Biosciences (KIN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

KMPH Average Annual Return
KND Average Annual Return
KOOL Average Annual Return
KPTI Average Annual Return
KRYS Average Annual Return
KTWO Average Annual Return
KURA Average Annual Return
LCI Average Annual Return
LGND Average Annual Return
LH Average Annual Return
More Healthcare companies »


KIN Average Annual Return 10 Years | | Copyright © 2021 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.